Clinical Trials
9 trialsNCT04673955 2022-09-29
BERING-CRC
Pierre Fabre Pharma GmbH
Recruiting
NCT01134666 2017-06-09
An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer
Merck KGaA, Darmstadt, Germany
Terminated
NCT01142869 2017-05-08
An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Merck KGaA, Darmstadt, Germany
Terminated
NCT01075828 2014-08-29
Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea
Merck KGaA, Darmstadt, Germany
Completed
NCT01082315 2014-08-29
A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment
Merck KGaA, Darmstadt, Germany
Completed
NCT01080066 2014-07-08
A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)
Merck KGaA, Darmstadt, Germany
Completed
NCT01075841 2014-07-02
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
Merck KGaA, Darmstadt, Germany
Withdrawn
NCT01074333 2014-06-17
An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
Merck KGaA, Darmstadt, Germany
Terminated
NCT00912327 2012-02-15
Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer
HiberCell, Inc.
Completed